<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169191</url>
  </required_header>
  <id_info>
    <org_study_id>SANE-02</org_study_id>
    <nct_id>NCT04169191</nct_id>
  </id_info>
  <brief_title>Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia</brief_title>
  <acronym>SANE-02</acronym>
  <official_title>Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia: An Open-label Dose-finding Clinical Trial (Phase Ib Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will determine the maximum tolerable dose of sildenafil and establish the
      pharmacokinetic and pharmacodynamic profile of sildenafil in human asphyxiated neonates
      treated with hypothermia. They will use a 3+3 design to escalate the sildenafil dose up to 6
      mg/kg/day (3mg/kg/dose q12h) in asphyxiated neonates demonstrating brain injury despite
      hypothermia treatment and assess whether we observe any beneficial effects of sildenafil on
      their brain and cardiopulmonary hemodynamics, without causing serious adverse events
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>3+3 design to escalate the sildenafil dose up to 6 mg/kg/day (3mg/kg/dose q12h)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>within first 10 days of life</time_frame>
    <description>Number of participants with death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypotension</measure>
    <time_frame>within first 10 days of life</time_frame>
    <description>Number of participants with hypotension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>within first 10 days of life</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Birth Asphyxia</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate</intervention_name>
    <description>Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates</description>
    <arm_group_label>Sildenafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female neonates meeting the criteria for induced hypothermia:

               -  Gestational age ≥ 36 weeks and birth weight ≥ 1800 g;

               -  Evidence of fetal distress, i.e., history of an acute perinatal event, cord pH ≤
                  7.0 or base deficit ≤ - 16 mEq/L;

               -  Evidence of neonatal distress, such as an Apgar score ≤ 5 at 10 minutes,
                  postnatal blood gas pH obtained within the first hour of life ≤ 7.0 or base
                  deficit ≤ - 16 mEq/L, or a continued need for ventilation initiated at birth and
                  continued for at least 10 minutes;

               -  Evidence of moderate to severe neonatal encephalopathy by an abnormal
                  neurological exam and/or an amplitude-integrated electroencephalogram (aEEG).

          -  Evidence of brain injury on a brain magnetic resonance imaging (MRI) performed on day
             2 of life.

        Exclusion Criteria:

          -  Neonates with complex congenital heart disease

          -  Neonates with cerebral malformations

          -  Neonates with genetic syndrome

          -  Neonates with intraventricular and/or intraparenchymal hemorrhage on MRI performed on
             day 2 of life
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pia Wintermark, MD</last_name>
    <phone>514-412-4452</phone>
    <email>pia.wintermark@mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pia Wintermark, MD</last_name>
      <phone>514-41-4452</phone>
    </contact>
    <investigator>
      <last_name>Pia Wintermark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Pia Wintermark</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Asphyxia Neonatorum</mesh_term>
    <mesh_term>Asphyxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to make individual participant data (IPD) available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

